FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML

Ellen Weisberg a,∗, Rosemary Barrett a, Qingsong Liu d,e, Richard Stone a,b,c, Nathanael Gray d,e, James D. Griffin a

a Department of Medical Oncology/Hematologic Neoplasia, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
b Department of Medicine, Harvard Medical School, Boston, MA, USA
c Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
d Dana Farber Cancer Institute, Department of Cancer Biology, Boston, MA, USA
e Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA

1. Introduction

There are around 15,000 newly diagnosed acute myelocytic leukemia (AML) patients in the US each year. This hematopoietic malignancy is characterized by aberrant proliferation of myeloid progenitor cells, coupled by a partial block in cellular differentiation (McKenzie, 2005). Permeation of bone marrow and peripheral blood with immature leukemic myeloblasts is the outcome of the abnormal survival advantage of leukaemic cells, and causes such symptoms as bleeding, anemia, and infection.

Current therapies for AML often do not succeed because of therapy-induced mortality or drug resistance (Estey, 2001). The use of conventional chemotherapeutic agents as a single treatment approach is coupled to a low therapy-induced mortality, however a high risk of relapse due to drug resistance (Mathews and DiPersio, 2004). In contrast, allogeneic transplantation (alloBMT) has a high therapy-induced mortality, and yet a lower risk of relapse (Mathews and DiPersio, 2004). Due to the fact that alloBMT shows more promise in younger patients, it has an overall small impact on the majority of AML patients, who tend to be aged 65 and older (Witherspoon and Deeg, 1999).

In AML, the activation of signaling pathways results from a range of genetic modifications leading to mutation of signaling molecules, such as receptor tyrosine kinases. Approximately 30% of AML patients, as well as a portion of ALL patients, harbor a mutant form of the class III receptor tyrosine kinase, FLT3 (Fms-Like Tyrosine kinase-3; STK-1, human Stem Cell Tyrosine Kinase-1; or FLK-2, Fetal Liver Kinase-2) (Stirewalt and Radich, 2003). Internal tandem duplications (ITD) within the juxtamembrane domain represent the most common form of constitutively activated FLT3, occurring in approximately 20–25% of AML patients and in less than 5% of myelodysplastic syndrome (MDS) patients (Nakao et al., 1996; Horiike et al., 1997; Kiyoi et al., 1998; Kondo et al., 1999; Rombouts et al., 2000; Kelly et al., 2002a,b). Indeed, a rapidly lethal myeloproliferative disorder in mice results from the in vivo transplantation of murine bone marrow cells infected with a FLT3-ITD-expressing retrovirus (Kelly et al., 2002a,b).

Also identified in AML patients are point mutations within the “activation loop” of FLT3 (Yamamoto et al., 2001). For example, a missense mutation in the aspartic acid residue at position 835 is...
believed to induce the activation loop into an “activated” configuration. Additional, albeit less prevalent, mutations in the kinase domain includes N841I (Jiang et al., 2004) and Y842C (Kindler et al., 2005).

Generally, the existence of a FLT3-ITD mutation translates into a poorer prognosis in both disease-free survival and overall survival (Mattison et al., 2007). In fact, patients harboring both a nucleophoshin 1 (NMP1) mutation, which is typically a positive prognostic indicator, and mutant FLT3 tend to have poorer outcomes (Mattison et al., 2007).

There are several inhibitors of FLT3 currently in clinical trials, and a number of novel inhibitors under preclinical investigation. However, the FLT3 inhibitors tested thus far clinically generally induce only partial and transient responses in patients when used as single agents. This suggests a need for the development of novel agents conferring higher potency and/or less toxicity that can either be used effectively as single agents or that can be effectively combined with other agents to suppress disease progression and prolong the lifespan of patients.

In addition to identifying and developing potent FLT3 inhibitors representative of novel and unique structural classes, there is a push toward gaining a better understanding of the mechanisms underlying drug resistance in AML. Clinical trial data with tyrosine kinase inhibitors show that while the peripheral blood blasts decline well, bone marrow responses are less common. Stromal cells have been implicated in this mode of resistance, as they provide viability signals to leukemic cells that protect them from the effects of the inhibitor. Other mechanisms of drug resistance include the emergence of point mutations in the target protein, and deregulation of signaling molecules associated with apoptotic signaling leading to a survival advantage in leukemic cells.

There are several strategies that may be effective in preventing relapse due to the emergence of point mutations in target proteins, as well as in overcoming drug resistance believed to be caused by stromal-mediated viability signals or deregulation of apoptotic signaling. These include the combined use of more than one FLT3 inhibitor, providing their interaction with FLT3 signaling or the FLT3 protein target is distinct enough for the two inhibitors to synergize. Alternatively, FLT3 inhibitors can be combined with small molecule inhibitors that interact with key components of major signaling pathways that play a significant role in AML. Finally, FLT3 inhibitors can be combined with standard chemotherapy as an approach to achieve maximum efficacy in patients.

2. Classes of FLT3 inhibitors

The structural classes of prominent FLT3 inhibitors in clinical trials or under preclinical investigation are shown in Fig. 1. The N-indolocarbazole PKC412 (midostaurin; N-benzoyl-staurosporine; Novartis Pharma AG) is one of several FLT3 inhibitors that is under going clinical testing, and which is currently in Phase III clinical trials. PKC412 is a broad spectrum, orally bioavailable inhibitor of FLT3, as well as platelet-derived growth factor β (PDGFRβ), c-KIT, and c-FMS (Weisberg et al., 2002). In preclinical studies, PKC412 caused cell cycle arrest and induced apoptosis in mutant FLT3-positive cells by directly inhibiting the activity of the FLT3 kinase, with an IC50 of approximately 0.01 μM in Ba/F3-FLT3-ITD cells, and inhibits FLT3-ITD phosphorylation with an IC50 of 30 nM (Weisberg et al., 2002). PKC412 induces apoptosis in mutant FLT3-expressing cells with no significant effect on cell cycle progression, however causes G2 arrest without apoptosis in wild-type FLT3-expressing cells (Odgerel et al., 2008).

In a Phase II clinical trial, PKC412 was generally well-tolerated, with a decrease in peripheral blast counts observed in roughly a third of PKC412-treated relapsed/refractory AML patients, and a median response duration of 13 weeks (Stone et al., 2004, 2005b). The hematological response rate in advanced AML patients treated with PKC412 was similar to that of CML blast crisis patients receiving imatinib. PKC412 is currently in Phase III clinical trials. In a Phase Ib clinical trial, newly diagnosed AML patients were treated with 50 mg po bid PKC412 in simultaneous and sequential combinations with daunorubicin and cytarabine induction and high-dose cytarabine consolidation. Clinical responses were complete (CR) in 12/13 mutant FLT3-positive patients (Stone et al., 2005a).

The related, orally administered indolocarbazole alkaloid CEP-701 (lestaurtinib; Cephalon), is an inhibitor of FLT3-ITD (Levis et al., 2002). CEP-701 has an IC50 of 5 nM against Ba/F3-FLT3-ITD cells, and inhibits FLT3-ITD phosphorylation with an IC50 of 3 nM (Levis et al., 2002). In addition to FLT3, protein targets for CEP-701 include TrkA and (vascular endothelial growth factor receptor) VEGFR (Levis et al., 2002). In early phase clinical trials, relapsed or refractory AML patients showed clinical responses of short duration to CEP-701 (Smith et al., 2003, 2004). A portion of patients showed complete inhibition of FLT3 autophosphorylation with no concomitant clinical response, while several others showed a decline in peripheral blood leukemic blasts to <5%. In a Phase II trial for older patients with AML not considered fit for intensive chemotherapy, transient clinical responses were observed (Knapper et al., 2006a,b). A Phase III trial has recently been completed for CEP-701, tested in relapsed AML patients harboring mutant FLT3. In addition, there is an ongoing Phase III clinical trial investigating the effects of chemotherapy plus CEP-701 in the UK that is enrolling both mutant FLT3- and wt FLT3-harboring patients. CEP-701 has also been tested in Phase II clinical trials for prostate cancer, and is in Phase I clinical trials with high risk neuroblastoma.

Another class of FLT3 inhibitors includes the 3-substituted indolinelones SU5416 and SU5614. SU5416 (semaxanib; SuGen) and SU5614 are both characterized inhibitors of FLT3 that also target c-KIT and VEGFR (Yee et al., 2002). SU5416 inhibits FLT3-ITD autophosphorylation with an IC50 of 100 nM and inhibits FLT3-ITD-positive cell proliferation with an IC50 of 250 nM. SU5614 inhibits FLT3-ITD autophosphorylation with an IC50 of 10 nM and inhibits FLT3-ITD-positive cell proliferation with an IC50 of 100 nM (Yee et al., 2002).

A multicenter Phase II clinical trial demonstrated SU5416 to inhibit FLT3 phosphorylation in refractory AML patients; incomplete clinical responses were observed in a portion of patients lasting from 1 to 5 months (Fiedler et al., 2003). SU5416 was investigated in another multicenter Phase II study, and showed modest clinical activity as a single agent in refractory AML patients; overall median survival was 12 weeks, with grade 3 or 4 drug-related toxicities possibly attributable to drug formulation (Giles et al., 2003). SU5416 was shown in a US Phase II hematological malignancy trial to inhibit FLT3 phosphorylation in refractory AML patients; the majority of treated patients, however, failed to achieve a clinical response (O’Farrell et al., 2004).

The orally administered indolinone derivative SU11248 (SU011248, sunitinib and Sutent; Pfizer) is equipotent against both FLT3-ITD and D835Y (Kancha et al., 2007). The growth of MV4-11 cells with no significant effect on cell cycle progression, however causes G2 arrest without apoptosis in wild-type FLT3-expressing cells (Odgerel et al., 2008).

In a Phase II clinical trial, PKC412 was generally well-tolerated, with a decrease in peripheral blast counts observed in roughly a third of PKC412-treated relapsed/refractory AML patients, and a
IC$_{50}$ of around 200 nM (Kelly et al., 2002a,b). Phase I trials were carried out to test the safety and tolerance of oral doses of MLN518 in AML patients; MLN518 was also tested in combination with standard induction chemotherapy for treatment of patients with newly diagnosed AML. MLN-518 showed limited activity as a single agent against AML and myelodysplastic syndrome, however caused 90% complete remissions in patients with newly diagnosed AML when given in combination with cytarabine and daunorubicin (Cheng and Paz, 2008). MLN518 is in ongoing Phase II clinical trials for progressive prostate and bone metastases and glioblastoma.
A Phase II study of MLN518 has been completed in patients with metastatic clear cell renal cell carcinoma, and a Phase I/II trial is recruiting for the testing of MLN518 against recurrent or progressive glioblastoma. A Phase II trial is recruiting for the testing of MLN518 in combination with bevacizumab against recurrent high-grade gliomas.

KW-2449, whose chemical structure is not yet disclosed, induces cell death in FLT3-ITD-positive cells and inhibits FLT3-ITD phosphorylation with an IC50 of 144 nM (Shiotsu et al., 2007, 2008; Pratz et al., 2009). Targets in addition to FLT3 include c-KIT and Aurora (Pratz et al., 2009). KW-2449 was tested in a Phase I clinical trial, in which transient decreases in peripheral blast counts were observed (Cortes et al., 2008; Pratz et al., 2009).

The N-(4-((3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea ABT-869 inhibited mutant FLT3-positive MV-4-11 and MOLM-13 with an IC50 of around 4–6 nM and demonstrated anti-leukemia activity in vivo (Albert et al., 2006; Shankar et al., 2007). ABT-869 has also demonstrated in vivo activity against AML harboring wild-type FLT3 (Zhou et al., 2008a). ABT-869, in addition to FLT3, includes PDGFR, KIT, and KDR (Shankar et al., 2007); ABT-869 is a multi-targeted inhibitor and is currently in Phase II clinical trials for metastatic breast cancer; advanced hepatocellular carcinoma, advanced colorectal cancer, and advanced renal cell carcinoma.

The benzimidazole-quinoline CHIR-258 (TK1258; Chiron) inhibits FLT3-ITD phosphorylation with an IC50 of 1 nM and kills MV4-11 cells with an IC50 of 13 nM (Lopes de Menezes et al., 2005). Targets, in addition to FLT3, include KIT, FMS, VEGFR, and FGFR (Lopes de Menezes et al., 2005). The agent caused tumor regressions and killing of AML cells in bone marrow in subcutaneous and bone marrow engraftment leukemia xenograft models (Lopes de Menezes et al., 2005). CHIR-258, which shows promise as an anti-multiple myeloma agent (Trudel et al., 2005), is being tested in Phase I clinical trials including those for multiple myeloma, mixed cytogenic leukemia, and unresectable hepatocellular carcinoma; it is currently in clinical trials for imatinib- and sunitinib-resistant GIST.

The hydroxystyryl-acylonitride LS104 inhibits FLT3-ITD activity and is cytotoxic against mutant FLT3-expressing cells (Kasper et al., 2008). Recently, a Phase I clinical trial enrolling patients with refractory or relapsed hematologic malignancies commenced for LS104.

AP24534 (Ariad) is a multi-targeted kinase inhibitor that inhibits the proliferation of mutant FLT3-positive cells with an IC50 of 13 nM (Zhang et al., 2008), and that inhibits mutant FLT3 phosphorylation with an IC50 of 2.8 nM and inhibits growth of MV4-11 cells with an IC50 of 0.88 nM (Auclair et al., 2007). Sorafenib was tested in a Phase I clinical trial for patients with refractory or relapsed AML and reduced the percentage of leukemia blasts in the bone marrow and peripheral blood of FLT3-ITD-positive AML patients (Zhang et al., 2008). Sorafenib has been FDA-approved for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma; it is currently in clinical trials for imatinib- and sunitinib-resistant GIST.

The hydroxystyryl-acylonitride LS104 inhibits FLT3-ITD activity and is cytotoxic against mutant FLT3-expressing cells (Kasper et al., 2008). Recently, a Phase I clinical trial enrolling patients with refractory or relapsed hematologic malignancies commenced for LS104.

AP24534 (Ariad) is a multi-targeted kinase inhibitor that inhibits the proliferation of mutant FLT3-positive cells with an IC50 of 13 nM, and that inhibits mutant FLT3 phosphorylation with an IC50 of 1 nM (Rivera et al., 2008). Other targets of AP24534 include c-KIT and FGFR (Rivera et al., 2008). AP24534 is in Phase I clinical trials for CML and other hematologic malignancies.

Reports of other FLT3 inhibitors in preclinical development include the quinazoline AG1295, which was specifically cytotoxic to FLT3-ITD-positive AML blasts (Levis et al., 2001); the quinazoline AG1296, selectively kills mutant FLT3-positive cell lines and primary AML cells, and inhibits FLT3-ITD autophosphorylation with an IC50 of approximately 1 μM (Tse et al., 2001, 2002); the (5-hydroxy-1H-2-indolyl)(1H-2-indolyl)methanone D64406 and the 5-butanoate-1H-2-indolyl)(1H-2-indolyl)-methanone D-65476, which displays an IC50 of around 0.2–0.3 μM against TEL-FLT3-transfected Ba/F3 cells (Tellier et al., 2002); the tricyclic quinoline AGL2043 (Gazit et al., 2003); the 1-phenyl-3H-8-oxa-2,3-diaza-cyclopenta[a]inden GTP-14564, which inhibits FLT3-ITD-expressing Ba/F3 cells at a concentration of 1 μM (Murata et al., 2003); the quinoline urea Ki23819, which has been shown to be effective against FLT3-ITD-expressing human cell lines (Komeno et al., 2005); KRN383, which inhibits FLT3-ITD autophosphorylation with an IC50 of less than 5.9 μM, DB35Y autophosphorylation with an IC50 of 43 nM, and proliferation of FLT3-ITD-positive cells with an IC50 of less than 2.9 nM and shows in vivo activity against FLT3-ITD-positive leukemia (Nishiyama et al., 2006); the 2,4,5-trisubstituted pyridinimide, Fl-700, which inhibits FLT3 kinase activity with an IC50 of 20 nM, inhibits the growth of MV4-11 cells with an IC50 of 14 nM, and displays in vivo anti-leukemia activity (Kiyoi et al., 2007); the quinoline Ki11502, which inhibits the proliferation of mutant FLT3-positive MV4-11 and MOLM13 with an IC50 of 0.5–0.6 μM and an IC50 of 37.54 nM against FLT3 kinase (Nishioka et al., 2008); 5-(1,3,4-oxidiazol-2-yl)pyrimidine derivatives, which show efficacy when administered orally in a MOLM-13 xenograft model (Ishida et al., 2008); the N,N′-diphenyl urea NVP-AST487, which selectively targets mutant FLT3 kinase activity, is able to overcome PKC412 resistance in vitro and synergizes with chemotherapeutic agents against mutant FLT3-positive cells, and inhibits the growth of FLT3-ITD-expressing cells in vivo (Weisberg et al., 2008b); the bis(1H-indol-2-yl)methanone compound 102, which overcomes resistance to PKC412, including PKC412 resistance due to mutated residue N676 in FLT3, and which synergizes with chemotherapeutic agents (Mahboobi et al., 2006; Heidel et al., 2009).

Other structural classes of FLT3 inhibitors include pyrimido-diazepines (Gracias et al., 2008), 4-amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes (Gaul et al., 2007), and the compound 102, which overcomes resistance to PKC412, including PKC412 resistance due to mutated residue N676 in FLT3, and which synergizes with chemotherapeutic agents (Mahboobi et al., 2006; Heidel et al., 2009).

Other structural classes of FLT3 inhibitors include pyrimido-diazepines (Gracias et al., 2008), 4-amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes (Gaul et al., 2007), and the 2-aclylaminothiophene-3-carboxamides (Patch et al., 2006).

### 3. Clinical resistance to FLT3 inhibition

#### While small molecule inhibitors of FLT3 are showing promise clinically for AML, thus far none has elicited sustained cytogenic responses as a single agent. For instance, quantitative measurement of FLT3 inhibition in patients treated with KW-2449 in a Phase I trial showed that inhibition of FLT3 occurred transiently to less than 20% of baseline (Pratz et al., 2009). It is possible that such incomplete and only temporary inhibition of FLT3 can be generalized to other FLT3 inhibitors under investigation and may be a primary reason for their limited clinical effectiveness (Chu and Small, 2009).

Possible mechanisms of drug resistance include:

(i) Acquired point mutations in the molecular targets (Shah et al., 2002; Cools et al., 2003). For example, resistance to PKC412 in one patient has been attributed to pre-existing or acquired mutations in the kinase domain of FLT3 (Heidel et al., 2006). Interestingly, it has recently been shown that different FLT3 kinase inhibitors, such as PKC412, SU5614, and sorafenib, display distinct and nonoverlapping resistance profiles (von Bubnoff et al., 2009). This suggests that combinations of FLT3 inhibitors may be beneficial therapeutically.

(ii) Other mechanisms include up-regulation of the anti-apoptotic protein, MCL-1, which is induced by a non-juxtamembrane ITD domain (FLT3ITD627E) (Breitenbuecher et al., 2009). This suggests that combinations of FLT3 inhibitors may be beneficial therapeutically.

(iii) Similarly, over-expression of survivin and enhanced activation of STAT signaling pathways has been found to mediate
resistance to the FLT3 inhibition (Zhou et al., 2009), as has over-expression of anti-apoptotic proteins of the BCL2 family, which can be overcome by the novel BH3 mimetic, ABT-737 (Kohl et al., 2007).

(iv) The potential importance of apoptosis-related signaling molecules in relation to FLT3 signaling is exemplified as well by the finding that constitutive activation of FLT3 is responsible for IKK activation, and both kinases are believed to act in the same anti-apoptotic pathway (Grosjean-Raillard et al., 2008). AS602868, which is an inhibitor of both IkappaB kinase 2 (IKK2) and FLT3, kills mutant FLT3-positive cells (Griessinger et al., 2007).

(v) There is considerable interest in investigating the contribution of the leukemia microenvironment to drug resistance of leukemic stem cells. Clinical studies of patients with advanced AML receiving FLT3 kinase inhibitors revealed a delayed or marginal decrease in bone marrow blasts, in contrast to a significant decrease in peripheral blasts. The survival of CD34+CD38-CD123+ leukaemic stem and progenitor cells was actually enhanced, as opposed to inhibited, by FLT3 inhibition in a defined “niche-like” in vitro microenvironment (Mony et al., 2008). Other studies have shown small-molecule CXCR4 inhibitors to be effective in enhancing chemotherapy- and FLT3 inhibitor-induced apoptosis of bone marrow stroma-protected AML cells in vitro and in vivo, implicating a causal relationship between chemokine receptor CXCR4 and stroma-derived factor 1alpha (SDF-1alpha) interaction and drug-resistant leukemia (Zeng et al., 2006, 2008; Nervi et al., 2008).

Specific stromal-secreted cytokines have been implicated in the protection of CML cells from cytotoxic, targeted agents (Weisberg et al., 2008a). We have found that the same panel of cytokines secreted in high concentration by the HS-5 human stromal cells are able to mimic the cytoprotective effect of stromal-conditioned media and can protect FLT3-ITD-positive cells from the inhibitory effects of PKC412 (Weisberg et al., unpublished data, Fig. 2).

These findings point toward the existence of a protective environment, or stromal-mediated chemoresistance. Such resistance could potentially be overcome by treatment with other agents, for example those interfering with apoptotic signaling (Weisberg et al., 2007). In addition, it may be possible to use the level of minimal residual disease as a short-term end point that could help assess the efficacy of targeted therapies like FLT3 inhibitors (Hess et al., 2009).

4. Combination therapy

The FLT3 inhibitors tested thus far generally induce only partial and transient responses in patients when administered as single agents. Thus, there is a need for the discovery and development of novel, more efficacious and less toxic inhibitors of FLT3 that could potentially be used effectively as single agents. There is also a need to test these, as well as FLT3 inhibitors under investigation, in combination with other therapeutics already in clinical use for leukemia.

Detection of drug-resistant leukemic blast cells in AML patients undergoing PKC412 therapy has led to such a search for novel, structurally diverse inhibitors of FLT3 that, if used in combination with conventional anti-leukemic agents, could potentially be successful in preventing the development of drug resistance. For example, SU11248 exhibits additive-to-synergistic inhibitory effects on FLT3-ITD-expressing cells when combined with cytarabine or daunorubicin (Yee et al., 2004). PKC412 synergizes with cytarabine, doxorubicin, idarubicin, mitoxantrone, etoposide, 4-hydroperoxycyclophosphamide and vincristine against mutant FLT3-positive cells, yet is antagonistic with cytarabine, doxorubicin, idarubicin, mitoxantrone, and etoposide against FLT3 mutant-negative leukemias (Mollgard et al., 2008; Furukawa et al., 2007). ABT-869 synergizes with cytarabine and doxorubicin against mutant FLT3-expressing cells (Zhou et al., 2008b).

4.1. Combination of FLT3 inhibitors with chemotherapy

The pharmacodynamic interrelationship between FLT3 inhibitors and chemotherapy in general seems to be sequence-dependent: the use of a FLT3 inhibitor prior to chemotherapy often results in antagonism, whereas the use of a FLT3 inhibitor following chemotherapy often translates into synergy (Patz and Levis, 2008). For example, CEP-701 is synergistic with cytarabine (Ara-C), daunorubicin, mitoxantrone, and etoposide, respectively, when administered simultaneously or immediately following their administration (Levis et al., 2004; Knapper et al., 2006a,b; Mead et al., 2008). The simultaneous combination of NVP-AST487 with Ara-C, doxorubicin, or PKC412 results in additive to synergistic effects (Weisberg et al., 2008b). The simultaneous administration of NVP-AST487 with Ara-C or doxorubicin leads to the strongest positive combination effect, which is similar to and comparable with sequential administration of Ara-C or doxorubicin 24 h prior to administration of NVP-AST487 (Weisberg et al., 2008b). However, the administration of NVP-AST487 24 h prior to either Ara-C or doxorubicin results in a slightly weaker combination effect as compared to the other regimens (Weisberg et al., 2008b). These findings suggest that FLT3 inhibitors could potentially be used in combination with standard chemotherapeutic agents currently in use for AML, and that the addition of inhibitors of FLT3 to AML chemotherapy regimens could potentially lead to improved clinical responses.
4.2. Combination of FLT3 inhibitors with other signaling inhibitors

Activating mutations in receptor tyrosine kinases like FLT3 represent obvious and key therapeutic targets when considering treatment strategies for AML. However, another salient- and related-feature of the malignancy that confers survival advantages is the common deregulation of one or more of the three signaling pathways: PI3K/PTEN/Akt/mTOR, RAS/Raf/MEK/ERK, and Jak/STAT, each frequently activated by mutations in upstream genes (Kornblau et al., 2006). The redundancy and simultaneous/cross-activation between the three pathways warrants consideration of the use of a multi-targeted therapeutic strategy, or the use of more than one type of signaling inhibitor (Fig. 3).

AKT, the downstream effector of PI3K, is activated through phosphorylation in the majority of cases of AML (Xu et al., 2003; Min et al., 2004; Tazzari et al., 2004; Grandage et al., 2005). Since FLT3-ITD mutations have been associated with AKT activation (Brandts et al., 2005), it has been suggested that the PI3K/AKT signaling pathway represents a critical, and shared, downstream target of these oncogenes. Wild-type FLT3, in response to ligand, activates pathways typical for type III tyrosine kinase receptors, including the PI3K/PTEN/Akt/mTOR, RAS/Raf/MEK/ERK and Jak/STAT pathways (LoPiccolo et al., 2008). Of these pathways, STAT5 is activated by signaling from FLT3-ITD (Y589 and Y591) and this is required for transformation in vivo (Rocnik et al., 2006). Notably, the activity of PKC412 against mutant FLT3-expressing cells is enhanced the novel dual PDK-1/PI3K inhibitor, BAG956, (Novartis Pharma AG) (Weisberg et al., 2008c).

Another important downstream effector of the PI3K/Akt signaling pathway, which mediates the effects of FLT3, is the highly conserved mammalian target of rapamycin (mTOR) (Giles and Albitar, 2005). Inhibition of mTOR with rapamycin inhibits proliferation of cells from patients with AML and FLT3 mutations (Recher et al., 2005). Of relevance, the combination of PKC412 and rapamycin is synergistic against cells expressing both PKC412-sensitive and PKC412-resistant mutant FLT3 (Mohi et al., 2004). In addition, the rapamycin derivative, RAD001, enhances the anti-leukemic activity of sunitinib (Ikezoe et al., 2006).

Inhibition of heat shock protein 90 (Hsp90), which chaperones mutant FLT3 but not wild-type FLT3, leads to disruption of the JAK/STAT, RAS/Raf/MEK/ERK, and PI3K/Akt signaling pathways, is effective in killing primary, mutant FLT3-positive AML cells (Shaer et al., 2008). Another novel agent, histone deacetylase inhibitor MS-275, inhibits the growth of mutant FLT3-positive cells with an IC50 of below 1 μM; this agent induces acetylation of Hsp90 in conjunction with ubiquination of FLT3, which leads to FLT3 degradation and disruption of signaling pathways mediated by ERK, Akt, and STAT5 (Nishioka et al., 2008a).

Clinical benefit could potentially arise from simultaneous inhibition of both FLT3 kinase activation and RAS/Raf/MEK/ERK signaling. For instance, inhibition of MEK1/2 kinases by the agent, AZD6244 (ARRY-142886), inhibits the proliferation of mutant FLT3-expressing cells and synergizes with the FLT3 kinase inhibitor, sunitinib (Nishioka et al., 2008b). In similar fashion, lonafarnib, a farnesyl-transferase inhibitor (FTI) positively combines with PKC412 against mutant FLT3-positive cells (Mollgard et al., 2008).

5. Conclusion

There is an urgent need for development of new treatment strategies that could lead to improved therapeutic efficacy in AML patients. Existing therapeutic approaches include the discovery and development of novel agents with unique structures conferring higher potency and selectivity toward FLT3 as a target. Such characteristics may allow for more complete inhibition of the FLT3 kinase protein target as compared to that of existing therapies in preclinical and clinical development. Elucidation of novel mechanisms of resistance that are associated with enhancement of leukemic cell survival, such as stromal-mediated chemoresistance and upregulation of anti-apoptotic signaling molecules, will warrant the testing and potential use of pro-apoptotic agents alone or in combination with FLT3 inhibitors. As a way to potentially suppress the emer-
References


